{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/prescribing-information/pregabalin/","result":{"pageContext":{"chapter":{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin","depth":2,"htmlHeader":"<!-- begin field d938d08e-7232-4845-80d6-5e9bc2a4c5d4 --><h2>Pregabalin</h2><!-- end field d938d08e-7232-4845-80d6-5e9bc2a4c5d4 -->","summary":"","htmlStringContent":"<!-- begin item d2d621a8-d968-4e5b-ae3e-9ebb833b25a4 --><!-- end item d2d621a8-d968-4e5b-ae3e-9ebb833b25a4 -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"27e41c4a-3581-556f-949c-99106fa04f8e","slug":"licensed-indication","fullItemName":"Licensed indication","depth":3,"htmlHeader":"<!-- begin field 7bad2660-a610-4909-a4cc-5984b6a53ab2 --><h3>Is pregabalin licensed for neuropathic pain?</h3><!-- end field 7bad2660-a610-4909-a4cc-5984b6a53ab2 -->","summary":"","htmlStringContent":"<!-- begin item 674ff97a-ab60-437a-9339-6f6455c374d6 --><!-- begin field dcf8368a-9730-473c-9d5c-7cf9647e1dcd --><ul><li>Pregabalin is licensed for the treatment of peripheral or central neuropathic pain in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020c</a>]. </li><li>However, the National Institute for Health and Care Excellence (NICE) recommends pregabalin as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">NICE, 2019a</a>]. </li></ul><!-- end field dcf8368a-9730-473c-9d5c-7cf9647e1dcd --><!-- end item 674ff97a-ab60-437a-9339-6f6455c374d6 -->","subChapters":[]},{"id":"9b3a219f-0f5d-562b-a2ce-b99283576fc6","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 27748b83-d2c9-41b2-bdb7-398d495af867 --><h3>Dose and titration</h3><!-- end field 27748b83-d2c9-41b2-bdb7-398d495af867 -->","summary":"","htmlStringContent":"<!-- begin item a74e8d39-1703-4361-af97-74b502fc7cdc --><!-- begin field 4a6a5ba4-78ce-4b69-a1e0-7660c17a77dd --><ul><li>The initial dose is 150 mg a day (given in two to three divided doses).<ul><li>A lower starting dose may be appropriate for some people, for example, people who cannot initially tolerate 150 mg a day or people with reduced renal function (see Table 1). Seek specialist advice and consult the manufacturer's Summary of Product Characteristics for use in people undergoing haemodialysis.</li></ul></li><li>If necessary, increase the dose after 3–7 days to 300 mg a day (given in two to three divided doses). The dose can be increased further to a maximum dose of 600 mg a day (given in two to three divided doses) after an additional 7-day interval.</li><li>Consider trialling pregabalin for 4 weeks before deciding it is not effective.</li><li>If pregabalin is not effective or not tolerated, discontinue treatment gradually over a minimum of 1 week.</li></ul><p><strong>Table 1.</strong> Recommended dosage adjustment for pregabalin in people with renal impairment.</p><table><thead><tr><th colspan=\"1\">Renal function (based on eGFR)</th><th colspan=\"1\">Starting daily dose</th><th colspan=\"1\">Maximum daily dose</th></tr></thead><tbody><tr><td colspan=\"1\">Stage 3 — moderate eGFR 30–60 mL per minute per 1.73 m<sup>2</sup></td><td colspan=\"1\">75 mg a day (in two to three divided doses)</td><td colspan=\"1\">300 mg a day (in two to three divided doses)</td></tr><tr><td colspan=\"1\">Stage 4 — severe eGFR 15–30 mL per minute per 1.73 m<sup>2</sup></td><td colspan=\"1\">25 to 50 mg a day (in one dose, or two divided doses)</td><td colspan=\"1\">150 mg a day (in one dose, or two divided doses)</td></tr><tr><td colspan=\"1\">Stage 5 — very severe or endstage eGFR less than 15 mL per minute per 1.73 m<sup>2</sup></td><td colspan=\"1\">25 mg once a day</td><td colspan=\"1\">75 mg once a day</td></tr><tr><td colspan=\"3\">eGFR = estimated glomerular filtration rate</td></tr><tr><td colspan=\"3\">Data from [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]  </p><!-- end field 4a6a5ba4-78ce-4b69-a1e0-7660c17a77dd --><!-- end item a74e8d39-1703-4361-af97-74b502fc7cdc -->","subChapters":[]},{"id":"c846af8e-24a1-5af9-9b1f-6a494819ba14","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0c067706-21f5-4d6f-bd14-c84327e779db --><h3>Contraindications and cautions </h3><!-- end field 0c067706-21f5-4d6f-bd14-c84327e779db -->","summary":"","htmlStringContent":"<!-- begin item 90a37652-2171-4263-856e-fb8cb8e469eb --><!-- begin field 65b92558-55ca-4c9d-a056-2778e08089d3 --><ul><li><strong>Prescribe pregabalin with caution to people with:</strong><ul><li>A history of substance abuse.</li><li>Conditions that may precipitate encephalopathy.</li><li>Diabetes mellitus. </li><li>Heart failure.</li><li>Renal impairment.</li><li>Severe congestive heart failure. </li></ul></li><li><strong>Also prescribe pregabalin with caution to people who are:</strong><ul><li>Elderly.  </li><li>At risk of falls.</li><li>At risk of suicide.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field 65b92558-55ca-4c9d-a056-2778e08089d3 --><!-- end item 90a37652-2171-4263-856e-fb8cb8e469eb -->","subChapters":[]},{"id":"e9bfa192-e228-5146-9af4-087a0396d38f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d400436b-a842-4b27-8859-c1ce63fedd7d --><h3>Adverse effects</h3><!-- end field d400436b-a842-4b27-8859-c1ce63fedd7d -->","summary":"","htmlStringContent":"<!-- begin item b2264f48-65ad-4220-ba81-6cb51f362a5f --><!-- begin field e82ffbec-faeb-4097-a72b-8d37c92efa5e --><ul><li><strong>Cardiac</strong> — tachycardia, first-degree atrioventricular block, sinus bradycardia,<em> </em>congestive heart failure (uncommon). <ul><li><strong>Rarely: </strong>QT interval prolongation, sinus tachycardia, sinus arrhythmia.</li></ul></li><li><strong>Eye </strong>— blurred vision, diplopia (common); peripheral vision loss, visual disturbance, eye swelling, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, increased lacrimation, eye irritation (uncommon).<ul><li><strong>Rarely:</strong> vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness.</li></ul></li><li><strong>Gastrointestinal</strong> — vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth (common); gastroesophageal reflux disease, salivary hypersecretion, oral hypoaesthesia (uncommon).<ul><li><strong>Rarely: </strong>ascites, pancreatitis, swollen tongue, dysphagia.</li></ul></li><li><strong>Metabolism and nutrition</strong> — increased appetite and weight gain. Some people with diabetes mellitus may need to adjust hypoglycaemic medicines.</li><li><strong>Musculoskeletal and connective tissue</strong> — muscle cramp, arthralgia, back pain, limb pain, cervical spasm (common); joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness (uncommon).<ul><li><strong>Rarely:</strong> rhabdomyolysis.</li></ul></li><li><strong>Nervous system</strong> — dizziness, somnolence, headache (very common); ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy (common); syncope, stupor, myoclonus, psychomotor hyperactivity, dyskinesia, intention tremor, nystagmus, cognitive disorder, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise (uncommon).<ul><li><strong>Rarely:</strong> convulsions, parosmia, hypokinesia, dysgraphia.</li></ul></li><li><strong>Psychiatric</strong> — euphoria, confusion, irritability, disorientation, insomnia, libido decreased (common); hallucination, panic attack, restlessness, agitation, depressed mood, elevated mood, aggression, depersonalisation, libido increased, anorgasmia, apathy (uncommon).<ul><li><strong>Suicidal thoughts and behaviour</strong>. There is a small increased risk of suicidal thoughts and behaviour associated with antiepileptic drugs (including pregabalin), which may be seen as early as 1 week after starting treatment.<ul><li>People should seek medical advice if they develop such thoughts or behaviour, and they should be referred for appropriate treatment if necessary.</li><li>Advise people taking pregabalin to be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">MHRA, 2008</a>].</li></ul></li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Dyspnoea, pulmonary oedema. </li><li>Elevated liver enzymes, jaundice, hepatitis.</li><li>Erectile dysfunction.</li><li>Hypotension, flushing.</li><li>Nasopharyngitis.</li><li>Oedema.</li><li>Rash, urticaria, pruritus, Stevens-Johnson syndrome.</li><li>Severe respiratory depression.</li><li>Urinary incontinence.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field e82ffbec-faeb-4097-a72b-8d37c92efa5e --><!-- end item b2264f48-65ad-4220-ba81-6cb51f362a5f -->","subChapters":[]},{"id":"4b5fb0ff-bf6a-517d-a865-62a1f5dc9351","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7e0f13fe-7276-443c-816c-cde01d8cb3d7 --><h3>Drug interactions </h3><!-- end field 7e0f13fe-7276-443c-816c-cde01d8cb3d7 -->","summary":"","htmlStringContent":"<!-- begin item d6841ac2-aff8-4000-a05a-448db040b3c7 --><!-- begin field b0c2f70c-3da2-464d-bf5a-33d210912604 --><ul><li><strong>Clozapine </strong>— levels may be increased if taken concurrently with pregabalin. Monitor for clozapine adverse effects (for example, agitation, dizziness, sedation, hypersalivation).</li><li><strong>Lacosamide</strong> — prolongation of the PR interval may occur with lacosamide, it should be used with caution in people taking pregabalin, which may also cause PR prolongation.</li><li><strong>Lorazepam</strong> — the sedative effect may be potentiated if taken concurrently with pregabalin. </li><li><strong>Orlistat </strong>— the levels of pregabalin may be reduced. </li><li><strong>Oxycodone</strong> — concurrent use may cause an additive impairment in cognitive and gross motor function.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Preston, 2016</a>]</p><!-- end field b0c2f70c-3da2-464d-bf5a-33d210912604 --><!-- end item d6841ac2-aff8-4000-a05a-448db040b3c7 -->","subChapters":[]},{"id":"cd2c75da-3353-51e4-b626-2074d36977ab","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 2609864b-0291-4cd2-889a-b83bbe08659b --><h3>Pregnancy and breastfeeding</h3><!-- end field 2609864b-0291-4cd2-889a-b83bbe08659b -->","summary":"","htmlStringContent":"<!-- begin item e93f6356-2803-4554-9d6a-ceb39f84fbcc --><!-- begin field aa7c8daa-9440-4b52-bddc-9d5cd775b742 --><h4>Pregnancy</h4><ul><li>Pregabalin should be avoided unless the benefit to the mother outweighs the risk to the fetus.</li><li>There are limited data on the use of pregabalin in women who are pregnant.<ul><li>If it is used, both mother and fetus should be monitored closely.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Limited data indicate that pregabalin is excreted in low amounts in breastmilk.<ul><li>Until more data become available, an alternate drug may be more suitable, especially while nursing a newborn or preterm infant.</li></ul></li><li>The manufacturer advises against using pregabalin when breastfeeding. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">UKTIS, 2016</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">LactMed, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field aa7c8daa-9440-4b52-bddc-9d5cd775b742 --><!-- end item e93f6356-2803-4554-9d6a-ceb39f84fbcc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}